Author:
Anselmino L. E.,Baglioni M. V.,Malizia F.,Laluce N. Cesatti,Etichetti C. Borini,Marignac V. L. Martínez,Rozados V.,Scharovsky O. G.,Girardini J.,Rico M. J.,Menacho Márquez M.
Abstract
AbstractDrug repositioning refers to new uses for existing drugs outside the scope of the original medical indications. This approach fastens the process of drug development allowing finding effective drugs with reduced side effects and lower costs. Colorectal cancer (CRC) is often diagnosed at advanced stages, when the probability of chemotherapy resistance is higher. Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer, highly metastatic and difficult to treat. For both tumor types, available treatments are generally associated to severe side effects. In our work, we explored the effect of combining metformin and propranolol, two repositioned drugs, in both tumor types. We demonstrate that treatment affects viability, epithelial-mesenchymal transition and migratory potential of CRC cells as we described before for TNBC. We show that combined treatment affects different steps leading to metastasis in TNBC. Moreover, combined treatment is also effective preventing the development of 5-FU resistant CRC. Our data suggest that combination of metformin and propranolol could be useful as a putative adjuvant treatment for both TNBC and CRC and an alternative for chemo-resistant CRC, providing a low-cost alternative therapy without associated toxicity.
Funder
Agencia Nacional de Promoción Científica y Tecnológica
Instituto Nacional del Cáncer
Consejo Nacional de Investigaciones Científicas y Técnicas
Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424. https://doi.org/10.3322/caac.21492 (2018).
2. Ballesteros, I. & Abriata, G. Vigilancia epidemiológica del cáncer. Análisis de Situación de Salud por Cáncer. Argentina, 2018 (Inst. Nac. Cáncer. Minist. Salud la Nación, 2018).
3. André, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27(19), 3109–3116. https://doi.org/10.1200/JCO.2008.20.6771 (2009).
4. Van Der Jeught, K., Xu, H. C., Li, Y. J., Lu, X. B. & Ji, G. Drug resistance and new therapies in colorectal cancer. World J. Gastroenterol. 24(34), 3834–3848. https://doi.org/10.3748/wjg.v24.i34.3834 (2018).
5. Kumar, P. & Aggarwal, R. An overview of triple-negative breast cancer. Arch. Gynecol. Obstet. 293(2), 247–269. https://doi.org/10.1007/s00404-015-3859-y (2016).
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献